<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177683</url>
  </required_header>
  <id_info>
    <org_study_id>MM08-141</org_study_id>
    <nct_id>NCT01177683</nct_id>
  </id_info>
  <brief_title>Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma</brief_title>
  <official_title>A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherif Farag, MB, BS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase I/II trial to determine the safety and the biologic activity of
      the bendamustine, bortezomib and pegylated liposomal doxorubicin combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2 IV
      over 1 hour, Day 4 Bendamustine escalating cohorts IV over 1 hour, Days 1 and 4 1 Cycle = 28
      days

      Phase II component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2
      IV over 1 hour, Day 4 Bendamustine at MTD IV over 1 hour, Days 1 and 4 Filgrastim (if defined
      in MTD) 5 µg/kg/day SC, Starting day 6 until neutrophil recovery to ANC &gt;1000

      1 Cycle = 28 days; Patients will continue treatment for a total of up to 8 cycles.

      ECOG Performance Status: 0-2

      Hematopoietic:

        -  Absolute neutrophil count (ANC) ≥ 1.2 x K/mm3

        -  Platelets ≥ 75 x K/mm3

      Hepatic:

        -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

        -  AST ≤ 2.5 x ULN

        -  ALT ≤ 2.5 x ULN

      Renal:

        -  Serum creatinine &lt; 3.0 mg/dL

      Cardiovascular:

        -  LVEF &gt;45% corrected by MUGA scan or echocardiogram.

        -  No unstable angina pectoris or recent myocardial infarction (within 6 months)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing Patient Response to Bendamustine - Phase I by assessing patient adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the maximum tolerated dose of bendamustine in association with bortezomib and pegylated liposomal doxorubicin in patients with relapsed or refractory Multiple Myeloma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate of Treatment Regimen - Phase II by assessing patient response rates</measure>
    <time_frame>8 months</time_frame>
    <description>Assess the overall response rate (CR+PR) of bendamustine in association with bortezomib and pegylated liposomal doxorubicin in patients with relapsed or refractory Multiple Myeloma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Treatment Regimen - Phase I and II by assessing patient adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Describe the toxicity of the combination of bendamustine with bortezomib and pegylated liposomal doxorubicin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Survival - Phase II by assessing patient survival times</measure>
    <time_frame>8 months</time_frame>
    <description>Evaluate the time to progression, overall survival, progression free survival, and duration of response of Multiple Myeloma patients treated with bendamustine, bortezomib and pegylated liposomal doxorubicin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bendamustine Pharmacokinetics - Phase II by evaluating patient samples</measure>
    <time_frame>8 months</time_frame>
    <description>Correlate bendamustine pharmacokinetics parameters (Cmax, t1/2, and AUC) at cycle 1 (and cycle 2) with patients' responses and correlate the DNA damage/repair at day 1 of cycle 1 and day 4 of cycle 2 with patients' responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Phase I component:
Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Phase I and II components:
Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Phase I and II components:
Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Phase II component:
Bendamustine at at MTD IV over 1 hour, Days 1 and 4</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Phase II component:
Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC &gt;1000</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A histologically established diagnosis of multiple myeloma with evidence of relapse or
             refractory disease.

          -  Must have a detectable serum or urine M-Protein by protein electrophoresis that is at
             least 500 mg/dL (serum) or 1 gm/24 hours (urine), respectively, or serum free light
             chain level &gt;100 mg/l for the involved free light chain.

          -  Must have received at least one (1) prior line of systemic treatment that has included
             either lenalidomide or thalidomide.

          -  Must be willing to provide correlative blood samples.

        Exclusion Criteria:

          -  Must not have received an excessive cumulative dose of anthracycline

          -  No ≥ grade 2 peripheral neuropathy.

          -  No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.

          -  No autologous stem cell transplant within 6 months prior to registration for protocol
             therapy

          -  No prior radiation therapy to &gt; 25% of bone marrow forming bones (i.e., pelvis) within
             30 days prior to registration for protocol therapy. See Study Procedures Manual to
             calculate percent of prior radiation.

          -  No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or
             equivalent) if given for management of co-morbid conditions.

          -  No known central nervous system involvement by myeloma.

          -  No poorly controlled intercurrent illness including, but not limited to, ongoing or
             active infection, poorly controlled diabetes, symptomatic congestive heart failure,
             cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the
             investigator would limit compliance with study requirements.

          -  No patients known to be positive for HIV, or active Hepatitis A, B, or C.

          -  No major surgery within 30 days prior to registration for protocol therapy. Placement
             of a venous access device within 30 days prior to registration for protocol therapy is
             allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif Farag, M.B., B.S.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Arnett Cancer Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Cancer Care</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Homepage</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Sherif Farag, MB, BS</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

